BACKGROUND: Individuals with ulcerative colitis (UC) are at increased risk for colorectal cancer. The standard method of surveillance for neoplasia in UC by colonoscopy is invasive and can miss flat lesions. We sought to identify a gene expression signature in nondysplastic mucosa without active inflammation that could serve as a marker for remote neoplastic lesions. METHODS: Gene expression was analyzed by complementary DNA microarray in 5 normal controls, 4 UC patients without dysplasia, and 11 UC patients harboring remote neoplasia. Common gene ontology pathways of significantly differentially expressed genes were identified. Expression of genes which were progressively and significantly upregulated from controls to UC without neoplasia, to UC with remote neoplasia were evaluated by real-time polymerase chain reaction. Several gene products were also examined by immunohistochemistry. RESULTS: Four hundred and sixty-eight genes were significantly upregulated, and 541 genes were significantly downregulated in UC patients with neoplasia compared with UC patients without neoplasia. Nine genes (ACSL1, BIRC3, CLC, CREM, ELTD1, FGG, S100A9, THBD, and TPD52L1) were progressively and significantly upregulated from controls to nondysplastic UC to UC with neoplasia. Immunostaining of proteins revealed increased expression of S100A9 and REG1α in UC-associated cancer and in nondysplastic tissue from UC patients harboring remote neoplasia compared with UC patients without neoplasia and controls. CONCLUSIONS: Gene expression changes occurring as a field effect in the distal colon of patients with chronic UC identify patients harboring remote neoplastic lesions. These markers may lead to a more accurate and less invasive method of detection of neoplasia in patients with inflammatory bowel disease.
BACKGROUND: Individuals with ulcerative colitis (UC) are at increased risk for colorectal cancer. The standard method of surveillance for neoplasia in UC by colonoscopy is invasive and can miss flat lesions. We sought to identify a gene expression signature in nondysplastic mucosa without active inflammation that could serve as a marker for remote neoplastic lesions. METHODS: Gene expression was analyzed by complementary DNA microarray in 5 normal controls, 4 UC patients without dysplasia, and 11 UC patients harboring remote neoplasia. Common gene ontology pathways of significantly differentially expressed genes were identified. Expression of genes which were progressively and significantly upregulated from controls to UC without neoplasia, to UC with remote neoplasia were evaluated by real-time polymerase chain reaction. Several gene products were also examined by immunohistochemistry. RESULTS: Four hundred and sixty-eight genes were significantly upregulated, and 541 genes were significantly downregulated in UC patients with neoplasia compared with UC patients without neoplasia. Nine genes (ACSL1, BIRC3, CLC, CREM, ELTD1, FGG, S100A9, THBD, and TPD52L1) were progressively and significantly upregulated from controls to nondysplastic UC to UC with neoplasia. Immunostaining of proteins revealed increased expression of S100A9 and REG1α in UC-associated cancer and in nondysplastic tissue from UC patients harboring remote neoplasia compared with UC patients without neoplasia and controls. CONCLUSIONS: Gene expression changes occurring as a field effect in the distal colon of patients with chronic UC identify patients harboring remote neoplastic lesions. These markers may lead to a more accurate and less invasive method of detection of neoplasia in patients with inflammatory bowel disease.
Authors: Mikael Benson; Michael A Langston; Mikael Adner; Bengt Andersson; Asa Torinssson-Naluai; Lars Olaf Cardell Journal: J Allergy Clin Immunol Date: 2006-05-11 Impact factor: 10.793
Authors: A Sekikawa; H Fukui; S Fujii; A Nanakin; N Kanda; Y Uenoyama; T Sawabu; H Hisatsune; T Kusaka; S Ueno; H Nakase; H Seno; T Fujimori; T Chiba Journal: Gut Date: 2005-05-24 Impact factor: 23.059
Authors: Martín C Abba; Hongxia Sun; Kathleen A Hawkins; Jeffrey A Drake; Yuhui Hu; Maria I Nunez; Sally Gaddis; Tao Shi; Steve Horvath; Aysegul Sahin; C Marcelo Aldaz Journal: Mol Cancer Res Date: 2007-09 Impact factor: 5.852
Authors: N J W de Wit; J Rijntjes; J H S Diepstra; T H van Kuppevelt; U H Weidle; D J Ruiter; G N P van Muijen Journal: Br J Cancer Date: 2005-06-20 Impact factor: 7.640
Authors: Joel Pekow; Alan L Hutchison; Katherine Meckel; Kymberly Harrington; Zifeng Deng; Nitya Talasila; David T Rubin; Stephen B Hanauer; Roger Hurst; Konstantin Umanskiy; Alessandro Fichera; John Hart; Aaron R Dinner; Marc Bissonnette Journal: Inflamm Bowel Dis Date: 2017-08 Impact factor: 5.325
Authors: Joel Pekow; Katherine Meckel; Urszula Dougherty; Yong Huang; Xindi Chen; Anas Almoghrabi; Reba Mustafi; Fatma Ayaloglu-Butun; Zifeng Deng; Haider I Haider; John Hart; David T Rubin; John H Kwon; Marc Bissonnette Journal: Clin Cancer Res Date: 2017-06-09 Impact factor: 12.531
Authors: Weicheng Liu; Yunzi Chen; Maya Aharoni Golan; Maria L Annunziata; Jie Du; Urszula Dougherty; Juan Kong; Mark Musch; Yong Huang; Joel Pekow; Changqing Zheng; Marc Bissonnette; Stephen B Hanauer; Yan Chun Li Journal: J Clin Invest Date: 2013-08-15 Impact factor: 14.808
Authors: Debashis Sahoo; Lee Swanson; Ibrahim M Sayed; Gajanan D Katkar; Stella-Rita Ibeawuchi; Yash Mittal; Rama F Pranadinata; Courtney Tindle; Mackenzie Fuller; Dominik L Stec; John T Chang; William J Sandborn; Soumita Das; Pradipta Ghosh Journal: Nat Commun Date: 2021-07-12 Impact factor: 14.919